SUWANEE, GA, March 20, 2018 (GLOBE NEWSWIRE) --
SANUWAVE Health, Inc. (OTCQB: SNWV) announces another installment of their blog, SHOCK THIS on its website, www.sanuwave.com. As with the previous blogs, this seventh installment is from SANUWAVE's head of Research and Development, Dr. Iulian Cioanta, and is titled "Shock Wave Applications in Medical Field – A Personal Prospective from One of the Lead and Renowned Researchers in the Field – Dr. Ching-Jen Wang." In 2017, the focus of SANUWAVE’s blog was education about shock waves. Many misconceptions still exist in the medical community about what a shock wave is and is not, and the blog has proven invaluable with regard to educating patients, healthcare professionals, and clinicians, both domestically and internationally. Education and training are a large part of our critical success factors, as a company, and the blog has been embraced. In 2018, our focus with the blogs will be on the opinions of avant-garde researchers in the shock wave field and on new ideas from experts using the shock wave technology. We will begin with our existing science advisors, then move into the wound care professionals and Key Opinion Leaders (KOLs) from around the globe. Starting with this new blog, we will present interviews with PIONEERS and INFLUENTIAL PERSONALITIES who have had significant contributions in advancing shock wave technology in the medical field, such as Dr. Ching-Jen Wang.
The interview with Dr. Wang occurred during SANUWAVE’s Clinical and Science Symposium at Chateau Elan, Braselton, GA, USA, in December 2017. Dr. Ching-Jen Wang and Dr. Iulian Cioanta conversed about the distinguished career of Dr. Wang, the latest advancements in shock wave technology, and the major role played by Dr. Wang in moving forward the shock wave technology in the tissue regeneration field. He is “one of the gurus” in the shock wave medical field. Please spend some time in the blog section of our site getting to know the company and technology even better.
The goal of the blog is to present a forum to educate customers, patients, partners, and the public about the various initiatives under way at SANUWAVE. The blog will also accept posts and comments (approved by SANUWAVE), which the Company views as valuable to the SANUWAVE community. This is expected to be a constructive forum for users from around the globe. By having a central location, SHOCK THIS, the Company can bring together in one setting various information that will be useful and entertaining to the SANUWAVE community. Members of the SANUWAVE community are encouraged to interact and reach out with thoughts and ideas, which will positively impact the SANUWAVE community as a whole. SANUWAVE Health, Inc. reserves the right to edit or exclude comments it deems not positively impacting the experience or is not appropriate from legal and regulatory perspectives.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.